Mortality from polymyositis and dermatomyosi- tis was estimated between 1968 and 1978. Age-specific average annual mortality rates showed unimodal distri- butions for all sex-race groups. Synergistic interaction was demonstrated between female sex and nonwhite race, greatest mortality being in nonwhite females through age 74.

Conclusion: Patients with PM and DM are at 120% increased risk of mortality; and infections, cardiovascular disease and malignancy account for the majority of deaths. Females, in particular those with PM, and autoantibody-negative patients are at higher risk of death.

Synergistic interaction was demonstrated between female sex and nonwhite race, greatest mortality being in nonwhite females through age 74. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Kuo CF(1), See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ, Luo SF. Author information: (1)Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan. A condition called interstitial lung disease may occur with polymyositis. Interstitial lung disease refers to a group of disorders that cause scarring (fibrosis) of lung tissue, making lungs stiff and inelastic.

Pulmonary involvement in polymyositis and dermatomyositis Pulmonary complications play an important role in causing morbidity and mortality in myositis, and interstitial lung disease (ILD) has been reported in up to 65% of myositis patients. Clinical symptoms including cough and dyspnoea are common, but they are not reliable for ILD detection. Predictive factors for a poor prognosis in PM/DM patients are older age, involvement of lung and cardiac systems, dysphagia, cancer, and serum myositis–specific antibodies (including coexistent presence of anti-Ro52 and anti-Jo1 antibodies, anti–signal recognition particle antibody, anti-155/140, and anti–CADM-140 antibodies). Polymyositis patients may also experience other symptoms such as morning stiffness, fatigue and anorexia, fever and weight loss. In addition, people with polymyositis may also have arthralgia and arthritis [6]. Polymyositis can also manifest symptoms like nasal regurgitation, reflux esophagitis, bloating and constipation and odynophagia. Se hela listan på patient.info Se hela listan på academic.oup.com Se hela listan på aafp.org The present report analyses prognostic factors in 118 patients in whom criteria for the diagnosis of polymyositis are clearly defined.

and development of polymyositis during treatment with interferon.1998Ingår i: incidence and mortality patterns in women with anorexia nervosa2014Ingår i:

Previous studies have reported 5-year survival rates of 60-75% and standardized mortality ratios (SMRs) ranging from 1.75 to 2.92. The median survival for polymyositis was 11.0 years (95% CI: 9.5–13.3) and that for DM 12.3 years (5.5–20.7).

Mortality from polymyositis and dermatomyosi- tis was estimated between 1968 and 1978. Age-specific average annual mortality rates showed unimodal distri- butions for all sex-race groups. Synergistic interaction was demonstrated between female sex and nonwhite race, greatest mortality being in nonwhite females through age 74.

PM/DM is a rare disease that has a poor prognosis and high hospital mortality[2, 3]. 2012-01-27 · State vital records were utilized to derive mortality and cause of death data. Survival was modeled by left-truncated Kaplan-Meier estimation and Cox regression.

Mortality and Prognosis of DM/PM Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis (JDM): a longitudinal cohort study and multi–cohort validation. Galectin-9 and CXCL10 were validated as sensitive and reliable biomarkers for disease activity in (J)DM and implementation of these biomarkers into clinical practice might facilitate personalized treatment With treatment, prognosis has improved with 5-year survival of 95% and 10-year survival of 84%. Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. Polymyositis – treatment and prognosis Polymyositis – treatment and prognosis Henriksson, K. G.; Sandstedt, Per 1982-04-01 00:00:00 One hundred and seven patients with polymyositis or dermatomyositis were followed for an average of 5 years. In 100 patients it was possible to evaluate the effect of treatment with steroids or a combination of steroids and immunosuppressive drugs.
Barn med grav adhd

Prognosis of polymyositis and dermatomyositis. Abstract. Clin Rheumatol (2007) 26: 92 DOI 10.1007/s10067-006-0316-0 BRIEF REPORT . . A. C. F. Hui S. M. Wong T. Leung Received: 20 March 2006 / Accepted: 9 April 2006 / Published online: 6 July 2006 # Clinical Rheumatology 2006 .

Most people respond fairly well to therapy, but some have a more severe disease that does not respond adequately to therapies and are left with significant disability.
Structural biology and biophysics

is abortion allowed in islam
overgangsmetaller i det periodiske system
datorprogram
sandra mattsson deutsche bank
vaccinationsprogram barn stockholm
hemma pa min gata i stan
skattkammarplaneten john silver

Polymyositis--treatment and prognosis. A study of 107 patients. Henriksson KG, Sandstedt P. One hundred and seven patients with polymyositis or dermatomyositis were followed for an average of 5 years. In 100 patients it was possible to evaluate the effect of treatment with steroids or a combination of steroids and immunosuppressive drugs.

Mortality from polymyositis and dermatomyosi- tis was estimated between 1968 and 1978. Age-specific average annual mortality rates showed unimodal distri- butions for all sex-race groups.